InnoCare Granted Clinical Trial Approval For Another Liquid Cancer Drug Candidate In China
July 09, 2022 at 20:20 PM EDT
InnoCare Pharma, which focuses on the treatment of cancer and autoimmune diseases, will look to further complete its product pipelines with the approval for its novel targeted protein degrader ICP-490.
